Montmorillonite

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Montmorillonite is a purified clay indicated in the treatment of intestinal pain and diarrhea.

Generic Name
Montmorillonite
DrugBank Accession Number
DB13654
Background

Not Available

Type
Small Molecule
Groups
Experimental, Investigational
Structure
Weight
Average: 360.307
Monoisotopic: 359.8254086
Chemical Formula
Al2H2O12Si4
Synonyms
  • Diosmectite
  • Montmorillonite
  • Montmorrillonite

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Treatment ofAcute diarrhoea••• •••
Treatment ofChronic functional diarrhea••• •••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
CarbamazepineMontmorillonite can cause a decrease in the absorption of Carbamazepine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Chenodeoxycholic acidMontmorillonite can cause a decrease in the absorption of Chenodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cholic AcidMontmorillonite can cause a decrease in the absorption of Cholic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
DeferasiroxMontmorillonite can cause a decrease in the absorption of Deferasirox resulting in a reduced serum concentration and potentially a decrease in efficacy.
Dehydrocholic acidMontmorillonite can cause a decrease in the absorption of Dehydrocholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
DIMECTAL Powder for Oral Suspension 3gPowder3 gOralPAHANG PHARMACY SDN. BHD.2021-12-02Not applicableMalaysia flag
FOTAGEL SUSPENSION 3g/20ml (DIOCTAHEDRAL SMECTITE)Suspension3 g/20mlOralIMEKS PHARMA SDN. BHD.2020-09-08Not applicableMalaysia flag
hovid Diosmectite Oral Suspension 1g/10mLSuspensionOralHovid Berhad2020-09-08Not applicableMalaysia flag
Smecta Orange-Vanilla Flavour Powder for Oral Suspension 3gPowder, for suspension3 gOralEP PLUS GROUP SDN. BHD.2020-09-08Not applicableMalaysia flag
SMECTA SACHET 3 g/sachetPowder3 g/sachetOralEMERGING PHARMA (S) PTE LTD1991-03-07Not applicableSingapore flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Dr. SEED Teatree and Lime Vegan No-sebum Cool Anti HairlossShampooMontmorillonite (0.088 g/100mL) + Lime (citrus) (0.0174 g/100mL) + Melaleuca alternifolia leaf (1 g/100mL)ShampooTopicalSaturday9 Co., Ltd.2023-02-21Not applicableUS flag

Categories

ATC Codes
A07BC05 — Diosmectite
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of inorganic compounds known as post-transition metal oxides. These are inorganic compounds containing an oxygen atom of an oxidation state of -2, in which the heaviest atom bonded to the oxygen is a post-transition metal.
Kingdom
Inorganic compounds
Super Class
Mixed metal/non-metal compounds
Class
Post-transition metal organides
Sub Class
Post-transition metal oxides
Direct Parent
Post-transition metal oxides
Alternative Parents
Post-transition metal salts / Metalloid salts / Inorganic salts / Inorganic oxides
Substituents
Inorganic metalloid salt / Inorganic oxide / Inorganic post-transition metal salt / Inorganic salt / Post-transition metal oxide
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
A585MN1H2L
CAS number
1318-93-0
InChI Key
GUJOJGAPFQRJSV-UHFFFAOYSA-N
InChI
InChI=1S/2Al.4O2Si.H2O.3O/c;;4*1-3-2;;;;/h;;;;;;1H2;;;/q2*+3;;;;;;3*-2
IUPAC Name
dialuminium(3+) ion tetrakis(silanedione) hydrate trioxidandiide
SMILES
O.[O--].[O--].[O--].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O

References

General References
  1. FDA Thailand Product Information: Dehecta (dioctahedral smectite) oral solution [Link]
  2. AIFA: Diosmectal (Montmorillonite) Oral Powder for Suspension [Link]
ChemSpider
32699070
RxNav
1425919
Wikipedia
Montmorillonite

Clinical Trials

Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package
PhaseStatusPurposeConditionsCountStart DateWhy Stopped100+ additional columns
4CompletedTreatmentAcute Diarrhea1somestatusstop reasonjust information to hide
4CompletedTreatmentBerberine / Coronavirus Disease 2019 (COVID‑19)1somestatusstop reasonjust information to hide
4CompletedTreatmentDiarrhea1somestatusstop reasonjust information to hide
4CompletedTreatmentGastroesophageal Reflux in Neonates1somestatusstop reasonjust information to hide
3CompletedTreatmentDiarrhea / Diarrhoea2somestatusstop reasonjust information to hide

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Powder, for solutionOral3 g
PowderOral3 g
Powder, for solutionOral78.97 g
Powder, for solutionOral
Powder, for suspensionOral3 G
ShampooTopical
Powder, for solutionOral3000 mg
PowderOral300000 g
SuspensionOral3 g/20ml
SuspensionOral
PowderOral3.000 g
SuspensionOral3.000 g
Powder, for suspensionOral30 g
SuspensionOral10 g
Powder, for suspensionOral
Powder, for suspensionOral3000 mg
PowderOral3 g/sachet
SuspensionOral3 g
Powder, for solutionOral300000 g
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP-0.66Chemaxon
pKa (Strongest Basic)-8.5Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count2Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area34.14 Å2Chemaxon
Rotatable Bond Count0Chemaxon
Refractivity2.89 m3·mol-1Chemaxon
Polarizability3.28 Å3Chemaxon
Number of Rings0Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleYesChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Drug created at June 23, 2017 20:46 / Updated at May 29, 2021 18:12